This section includes the currently available and published information from a literature search (12th June 2015).
Summary of Product Characteristics
Please click on the links below to find out more on the European summary of product characteristics for each agent:
- European Medicines Agency. Vemurafenib (ZELBORAF) Summary of Product Characteristics. 2015.
- European Medicines Agency. Trametinib (MEKINIST). Summary of Product Characteristics. 2015.
- European Medicines Agency. Ruxolitinib (JAKAVI) Summary of Product Characteristics. 2015.
- European Medicines Agency. Ponatinib (ICLUSIG). Summary of Product Characteristics. 2015.
- European Medicines Agency. Pazopanib (VOTRIENT) Summary of Product Characteristics. 2015.
- European Medicines Agency. Nintedanib (VARGATEF). Summary of Product Characteristics. 2015.
- European Medicines Agency. Nilotinib (TASIGNA). Summary of Product Characteristics 2015.
- European Medicines Agency. Lapatinib (TYVERB). Summary of Product Characteristics. 2015.
- European Medicines Agency. Ibrutinib (IMBRUVICA). Summary of Product Characteristics. 2015.
- European Medicines Agency. Gefitinib (IRESSA). Summary of Product Characteristics. 2015.
- European Medicines Agency. Erlotinib (TARCEVA). Summary of Product Characteristics. 2015.
- European Medicines Agency. Dasatanib (SPRYCEL) Summary of Product Characteristics. 2015.
- European Medicines Agency. Dabrafenib (TAFINLAR) Summary of Product Characteristics. 2015.
- European Medicines Agency. Crizotinib (XALKORI) Summary of Product Characteristics. 2015.
- European Medicines Agency. Cabozantinib (COMETRIQ) Summary of Product Characteristics. 2015.
- European Medicines Agency. Bosutinib (BOSULIF) Summary of Product Characteristics. 2015.
- European Medicines Agency. Axitinib (INLYTA) Summary of Product Characteristics. 2015.
- European Medicines Agency. Afatinib (GIOTRIF) Summary of Product Characteristics. 2015.
- European Medicines Agency. Vemurafenib (ZELBORAF). Summary of Product Characteristics. 2015.
- European Medicines Agency. Imatinib (GLIVEC). Summary of Product Characteristics. 2015.
- European Medicines Agency. Vandetanib (CAPRELSA). Summary of Product Characteristics. 2015.
- European Medicines Agency. Imatinib (GLIVEC). Summary of Product Characteristics. 2015.
- European Medicines Agency. Sunitinib (SUTENT). Summary of Product Characteristics. 2015.
- European Medicines Agency. Sorafenib (NEXAVAR). Summary of Product Characteristics. 2015.
- European Medicines Agency. Regorafenib (STIVARGA). Summary of Product Characteristics. 2015.
- European Medicines Agency. Lenvatinib (Lenvima). Summary of Product Characteristics. 2015.
- European Medicines Agency. Idelalisib (ZYDELIG) Summary of Product Characteristics. 2015.
- European Medicines Agency. Ceritinib (ZYKADIA) Summary of Product Characteristics. 2015.
Note: The most recent versions can be found on the European Medicines Agency website.
Editorials
Review Articles
- Bardin C, Veal G, Paci A et al. Therapeutic drug monitoring in cancer--are we missing a trick? Eur J Cancer 2014; 50: 2005-2009.
- Bryant L, Fishman T. Clinically important drug-drug interactions and how to manage them. J Prim Health Care 2009; 1: 150-151.
- Buajordet I, Ebbesen J, Erikssen J et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327-341.
- Budha NR, Frymoyer A, Smelick GS et al. Drug absorption interactions between oral targeted anti-cancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 2012; 92: 203-213.
- Haouala A, Widmer N, Duchosal MA et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117: e75-87.
- Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anti-cancer agents. Nat Rev Clin Oncol 2014; 11: 272-281.
- Pajares B, Torres E, Trigo JM et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol 2012; 14: 94-101.
- Riechelmann RP, Tannock IF, Wang L et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600.
- Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015; 79: 241-253.
- van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315-326.
- Tascilar M, de Jong FA, Verweij J, Mathijssen RH. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11: 732-741.